Treatment of fatal disseminated herpes simplex virus, type 1, infection in immunosuppressed mice (39899).
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006561:Herpes Simplex / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D007065:Idoxuridine / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D007372:Interferons / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D008297:Male; D051379:Mice; D011070:Poly I-C / Q000627:therapeutic use; D018139:Simplexvirus / Q000302:isolation & purification; D013601:T-Lymphocytes / Q000276:immunology; D014740:Vidarabine / Q000627:therapeutic use
D000998:Antiviral Agents; D003561:Cytarabine; D007372:Interferons; D014740:Vidarabine; D007065:Idoxuridine; D011070:Poly I-C